Candida albicans intralesional injection immunotherapy of warts

Cutis
|October 2, 2002
PubMed

Insights

Intralesional Candida immunotherapy offers a safe, effective, and inexpensive treatment for common warts (verruca vulgaris), including difficult plantar warts. This novel approach may also lead to the regression of untreated warts.

Area of Science:

  • Dermatology
  • Immunology
  • Infectious Diseases

Background:

  • Verrucae treatment poses challenges due to pain, scarring, ineffectiveness, and cost.
  • Conventional therapies for verruca vulgaris often yield suboptimal patient outcomes.

Purpose of the Study:

  • To compare the clinical outcomes and safety of intralesional Candida albicans immunotherapy (CI) against conventional wart treatments.
  • To evaluate CI as a novel therapeutic modality for verruca vulgaris, including plantar warts.

Main Methods:

  • Prospective, nonrandomized, open-label comparative study design.
  • Utilized intralesional injection of Candida extract for immunotherapy.
  • Compared outcomes with standard wart treatment protocols.

Main Results:

  • Intralesional Candida immunotherapy (CI) demonstrated safety and tolerability.
  • CI proved effective for multiple warts, including plantar and recalcitrant types.
  • Observed regression in uninjected warts during CI treatment, a phenomenon termed postimmunotherapy-revealed cicatrix (PIRC).

Conclusions:

  • CI is a novel, simple, and cost-effective treatment for verruca vulgaris.
  • CI is well-suited for various wart presentations and difficult-to-treat cases.
  • CI represents an off-label use of Candida extract with promising therapeutic potential.

Related Concept Videos